The Human Plasmin-Derived Light (B) Chain·Streptokinase Complex: A Second-Generation Thrombolytic Agent

Summary

Specific assay methods for the human plasmin-derived light (B) chain · streptokinase (B·SK) complex, in terms of both streptokinase (SK) and urokinase (UK) International Units, are described. The kinetic properties of various SK activator complexes with plasminogen, Val ₄₄₂-plasmin, and the plasmin-derived light (B) chain were compared to SK in terms of their catalytic efficiencies and Lineweaver-Burk plots. Similar kinetic data, and Lineweaver-Burk plots, are described for both highly purified high-molecular weight UK and low-molecular weight UK, including different clinical UK preparations. The B·SK complex has the highest catalytic efficiency of all the activator species studied. The Lineweaver-Burk plots of each of the various activator species are “fingerprints” of the enzymatic character of the activator. The B-SK complex is more like UK than SK, as an activator, in activating non-human plasminogen species. The biological halflife of the B·SK complex, in a dog model, was determined to be about 4 hr which is longer than the biological half-life(s) of SK in the same animal model, namely 0.6 hr (47%) and 2.8 hr (53%). This new second-generation activator complex may prove to be a useful thrombolytic agent in the treatment of thromboembolic diseases.

Keywords

Streptokinase·plasminogen and plasmin-derived complexes - Urokinase species - Catalytic efficiencies of plasminogen activators - Biological half-lives of plasminogen activators

• References

• 1 Robbins KC, Markus G. The interaction of human plasminogen with strepto-kinase. In: Fibrinolysis: Current Fundamental and Clinical Concepts. Gaffney PJ, Ulutin SB. (eds) Academic Press; London: 1978. pp 61-75
• 2 Summaria L, Robbins KC. Isolation of a human plasmin-derived, functionally active, light (B) chain capable of forming with streptokinase an equimolar light (B) chain streptokinase complex with plasminogen activator activity. J Biol Chem 1976; 251: 5810-5813
• 3 Summaria L, Boreisha IG, Arzadon L, Robbins KC. The dissolution of human cross-linked plasma fibrin clots by the equimolar human plasmin-derived light (B) chain o streptokinase complex. The acceleration of clot lysis by pretreatment of fibrin clots with the light (B) chain Thromb Res 1977; 11: 377-389
• 4 Wohl RC, Summaria L, Robbins KC. Kinetics of activation of human plasminogen by different activator species at pH 7.4 and 37°C. J Biol Chem 1980; 255: 2005-2013
• 5 Wohl RC, Summaria L, Robbins KC. Physiological activation of the human fibrinolytic system. Isolation and characterization of human plasminogen variants, Chicago I and Chicago II J Biol Chem 1979; 254: 9063-9069
• 6 Wohl RC, Summaria L, Chediak J, Rosenfeld S, Robbins KC. Human plasminogen variant Chicago III. Thromb Haemostas 1982; 48: 146-152
• 7 Summaria L, Boreisha IG, Wohl RC, Robbins KC. Recombinant human Lysplasmin and the Lys-plasmin-streptokinase complex. J Biol Chem 1979; 254: 6811-6814
• 8 Gallimore MJ. Inhibitors of plasminogen activation present in human plasma. In: The Physiological Inhibitors of Blood Coagulation and Fibrinolysis. Collen D, Wiman B, Verstraete M. (eds) Elsevier, North-Holland, Biomedical Press; Amsterdam: 1979. pp 199-217
• 9 Robbins KC, Summaria L. Plasminogen and plasmin. In: Methods in Enzymology. Lorand L. (ed) Academic Press; New York: 1976. 45 257-273
• 10 Robbins KC, Summaria L. Human plasminogen and plasmin. In: Methods in Enzymology. Perlman GE, Lorand L. (eds) Academic Press; New York: 1970. 19 184-199
• 11 Barlow GH. Urinary and kidney cell plasminogen activator. In: Methods in Enzymology. Lorand L. (eds) Academic Press; New York: 1976. 45 239-244
• 12 Chase Jr T, Shaw E. Comparison of the esterase activities of trypsin plasmin and thrombin on guanidinobenzoate esters. Titration of the enzymes Bio-chemistry 1969; 8: 2212-2224
• 13 Heller VG, Paul H. Changes in cell volume produced by varying concentration of different anticoagulants. J Lab Clin Med 1934; 19: 777-780
• 14 Collen D, Tytgatt GN, Claeys H, Verstraete M, Wallén P. Metabolism of plasminogen in healthy subjects: Effect of tranexamic acid. J Clin Invest 1972; 51: 1310-1318
• 15 Collen D, Semeraro N, Tricot JP, Vermylen J. Turnover of fibrinogen, plasminogen and prothrombin during exercise in man. J AppI Physiol 1977; 42: 865-873
• 16 Greenblatt DJ, Koch-Weser J. Clinical pharmacokinetics. N Engl J Med 1975; 293: 702-705
• 17 Piessens R, Collen D, Tytgatt GN. Computer analysis of fibrinogen tracer data. Comput Biomed Res 1971; 4: 585-593
• 18 Ardaillou N, Sraer JD, Beufils P. Fibrinogen kinetics in chronic renal failure of various causes. Biomedicine 1974; 21: 49-56
• 19 Ardaillou N, Dray L, Budzyński AZ, Marder VJ, Larrieu MJ. The half-life of plasmic degradation products of human fibrinogen in rabbits. Thromb Haemostas 1977; 37: 201-209
• 20 Snedecor GW, Cochran WG. Statistical Methods, 6th Ed. The Iowa State University Press; Ames, Iowa: 1976
• 21 Wohl RC, Sinio L, Summaria L, Robbins KC. Comparative activation kinetics of mammalian plasminogens. Biochim Biophys Acta 1983; 745: 20-31
• 22 Som P, Rhodes BA, Bell WR. Radiolabeled streptokinase and urokinase and their comparative distribution. Thromb Res 1975; 6: 247-253
• 23 Summaria L, Arzadon L, Bernabe P, Robbins KC. The interaction of streptokinase with human cat, dog, and rabbit plasminogens. The fragmentation of streptokinase in the equimolar plasminogen-streptokinase complexes J Biol Chem 1974; 249: 4760-4769
• 24 Alkjaersig N, Fletcher A. Metabolism of urokinase. In: Thrombosis and Urokinase. Paoletti R, Sherry S. (eds) Academic Press; London: 1977. pp 129-141
• 25 Pfeifer GW, Doerr F, Brod KH. Zur Pharmakokinetik von ¹³¹I-Streptokinase am Menschen. Klin Wschr 1969; 47: 482-486
• 26 Matsuo O. Turnover of tissue plasminogen activator in man. Thromb Haemostas 1982; 48: 242